A Phase 3 Study of Donafenib in Patients With Radioiodine-refractory Differentiated Thyroid Cancer
Status:
Recruiting
Trial end date:
2021-10-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, double-blind, placebo-controlled Phase 3 study to compare
the progression free survival, overall response rate (ORR) and safety of participants treated
with Donafenib 0.3g Bid by continuous oral dosing versus placebo.